Immuneering Corp (IMRX)
2.48
+0.11
(+4.64%)
USD |
NASDAQ |
Oct 04, 16:00
2.48
0.00 (0.00%)
After-Hours: 20:00
Immuneering SG&A Expense (Annual): 16.76M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.76M |
| December 31, 2022 | 15.61M |
| December 31, 2021 | 8.272M |
| Date | Value |
|---|---|
| December 31, 2020 | 3.11M |
| December 31, 2019 | 2.709M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
2.709M
Minimum
2019
16.76M
Maximum
2023
9.292M
Average
8.272M
Median
2021
SG&A Expense (Annual) Benchmarks
| Singular Genomics Systems Inc | 54.48M |
| Biomarin Pharmaceutical Inc | 937.30M |
| Integra Lifesciences Holdings Corp | 656.64M |
| Eton Pharmaceuticals Inc | 18.93M |
| Tenon Medical Inc | 13.80M |